PIM3 Kinase: A Promising Novel Target in Solid Cancers
PIM3 (provirus-integrating Moloney site 3) is a serine/threonine kinase and belongs to the PIM family (PIM1, PIM2, and PIM3). PIM3 is a proto-oncogene that is frequently overexpressed in cancers originating from endoderm-derived tissues, such as the liver, pancreas, colon, stomach, prostate, and bre...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/16/3/535 |
| _version_ | 1797319011920248832 |
|---|---|
| author | Pinar Atalay Bulent Ozpolat |
| author_facet | Pinar Atalay Bulent Ozpolat |
| author_sort | Pinar Atalay |
| collection | DOAJ |
| description | PIM3 (provirus-integrating Moloney site 3) is a serine/threonine kinase and belongs to the PIM family (PIM1, PIM2, and PIM3). PIM3 is a proto-oncogene that is frequently overexpressed in cancers originating from endoderm-derived tissues, such as the liver, pancreas, colon, stomach, prostate, and breast cancer. PIM3 plays a critical role in activating multiple oncogenic signaling pathways promoting cancer cell proliferation, survival, invasion, tumor growth, metastasis, and progression, as well as chemo- and radiation therapy resistance and immunosuppressive microenvironment. Genetic inhibition of PIM3 expression suppresses in vitro cell proliferation and in vivo tumor growth and metastasis in mice with solid cancers, indicating that PIM3 is a potential therapeutic target. Although several pan-PIM inhibitors entered phase I clinical trials in hematological cancers, there are currently no FDA-approved inhibitors for the treatment of patients. This review provides an overview of recent developments and insights into the role of PIM3 in various cancers and its potential as a novel molecular target for cancer therapy. We also discuss the current status of PIM-targeted therapies in clinical trials. |
| first_indexed | 2024-03-08T03:59:44Z |
| format | Article |
| id | doaj.art-888a8093167e4532b66f44081bb4ab59 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-08T03:59:44Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-888a8093167e4532b66f44081bb4ab592024-02-09T15:08:55ZengMDPI AGCancers2072-66942024-01-0116353510.3390/cancers16030535PIM3 Kinase: A Promising Novel Target in Solid CancersPinar Atalay0Bulent Ozpolat1Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USADepartment of Nanomedicine, Houston Methodist Research Institute, Houston, TX 77030, USAPIM3 (provirus-integrating Moloney site 3) is a serine/threonine kinase and belongs to the PIM family (PIM1, PIM2, and PIM3). PIM3 is a proto-oncogene that is frequently overexpressed in cancers originating from endoderm-derived tissues, such as the liver, pancreas, colon, stomach, prostate, and breast cancer. PIM3 plays a critical role in activating multiple oncogenic signaling pathways promoting cancer cell proliferation, survival, invasion, tumor growth, metastasis, and progression, as well as chemo- and radiation therapy resistance and immunosuppressive microenvironment. Genetic inhibition of PIM3 expression suppresses in vitro cell proliferation and in vivo tumor growth and metastasis in mice with solid cancers, indicating that PIM3 is a potential therapeutic target. Although several pan-PIM inhibitors entered phase I clinical trials in hematological cancers, there are currently no FDA-approved inhibitors for the treatment of patients. This review provides an overview of recent developments and insights into the role of PIM3 in various cancers and its potential as a novel molecular target for cancer therapy. We also discuss the current status of PIM-targeted therapies in clinical trials.https://www.mdpi.com/2072-6694/16/3/535PIM3PIM kinase inhibitorstargeted therapiesserine/threonine kinasesolid cancertriple-negative breast cancer |
| spellingShingle | Pinar Atalay Bulent Ozpolat PIM3 Kinase: A Promising Novel Target in Solid Cancers Cancers PIM3 PIM kinase inhibitors targeted therapies serine/threonine kinase solid cancer triple-negative breast cancer |
| title | PIM3 Kinase: A Promising Novel Target in Solid Cancers |
| title_full | PIM3 Kinase: A Promising Novel Target in Solid Cancers |
| title_fullStr | PIM3 Kinase: A Promising Novel Target in Solid Cancers |
| title_full_unstemmed | PIM3 Kinase: A Promising Novel Target in Solid Cancers |
| title_short | PIM3 Kinase: A Promising Novel Target in Solid Cancers |
| title_sort | pim3 kinase a promising novel target in solid cancers |
| topic | PIM3 PIM kinase inhibitors targeted therapies serine/threonine kinase solid cancer triple-negative breast cancer |
| url | https://www.mdpi.com/2072-6694/16/3/535 |
| work_keys_str_mv | AT pinaratalay pim3kinaseapromisingnoveltargetinsolidcancers AT bulentozpolat pim3kinaseapromisingnoveltargetinsolidcancers |